Research Analysts Issue Forecasts for PDSB Q1 Earnings

PDS Biotechnology Corporation (NASDAQ:PDSB) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of PDS Biotechnology in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.15) for the quarter. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.20) EPS.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.06.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Stock Up 12.8%

PDSB stock opened at $0.61 on Wednesday. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. The firm has a 50 day simple moving average of $0.70 and a 200-day simple moving average of $0.85. The company has a market capitalization of $31.68 million, a P/E ratio of -0.81 and a beta of 1.20. PDS Biotechnology has a twelve month low of $0.51 and a twelve month high of $1.92.

Institutional Investors Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP boosted its holdings in PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after purchasing an additional 80,937 shares during the period. Squarepoint Ops LLC increased its stake in PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after purchasing an additional 156,662 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of PDS Biotechnology by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after purchasing an additional 38,399 shares during the period. Armistice Capital LLC acquired a new stake in shares of PDS Biotechnology during the fourth quarter worth $2,182,000. Finally, Commonwealth Equity Services LLC lifted its position in shares of PDS Biotechnology by 117.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after buying an additional 106,300 shares during the last quarter. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.